Leerink Partnrs Predicts DexCom's Q1 Earnings (NASDAQ:DXCM)

DexCom, Inc. (NASDAQ:DXCM - Free Report) - Investment analysts at Leerink Partnrs lifted their Q1 2025 earnings per share estimates for DexCom in a research report issued on Friday, February 14th. Leerink Partnrs analyst M. Kratky now expects that the medical device company will post earnings per share of $0.31 for the quarter, up from their prior estimate of $0.30. The consensus estimate for DexCom's current full-year earnings is $2.02 per share. Leerink Partnrs also issued estimates for DexCom's Q2 2025 earnings at $0.51 EPS and FY2029 earnings at $3.67 EPS.

Several other analysts have also weighed in on DXCM. Royal Bank of Canada cut their price objective on DexCom from $120.00 to $115.00 and set an "outperform" rating for the company in a report on Friday, October 25th. Canaccord Genuity Group raised their price objective on shares of DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a research report on Friday, February 14th. Citigroup boosted their target price on shares of DexCom from $85.00 to $91.00 and gave the stock a "buy" rating in a report on Wednesday, December 11th. Morgan Stanley raised their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a report on Friday, February 14th. Finally, Redburn Atlantic raised DexCom from a "neutral" rating to a "buy" rating and upped their price target for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, DexCom currently has an average rating of "Moderate Buy" and a consensus price target of $99.06.

DexCom Price Performance

NASDAQ:DXCM traded down $0.34 during midday trading on Monday, hitting $89.34. 3,340,262 shares of the stock were exchanged, compared to its average volume of 3,629,790. The company has a market capitalization of $34.90 billion, a price-to-earnings ratio of 62.48, a P/E/G ratio of 2.33 and a beta of 1.14. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. DexCom has a one year low of $62.34 and a one year high of $142.00. The business has a 50-day moving average price of $83.06 and a two-hundred day moving average price of $75.85.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%.

Insiders Place Their Bets

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of the firm's stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the sale, the chief executive officer now directly owns 319,037 shares in the company, valued at $27,727,505.67. This trade represents a 9.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the sale, the chief operating officer now owns 268,644 shares of the company's stock, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,083 shares of company stock valued at $3,309,794 over the last three months. 0.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On DexCom

Several large investors have recently added to or reduced their stakes in DXCM. Versant Capital Management Inc acquired a new position in shares of DexCom in the fourth quarter valued at $25,000. Private Trust Co. NA increased its holdings in DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after buying an additional 245 shares during the period. Optiver Holding B.V. bought a new stake in DexCom in the 4th quarter valued at $33,000. TD Private Client Wealth LLC raised its stake in shares of DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after buying an additional 167 shares in the last quarter. Finally, Larson Financial Group LLC lifted its holdings in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after acquiring an additional 137 shares during the period. Institutional investors and hedge funds own 97.75% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.